Interleukin-6 and cachexia in ApcMin/+ mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 294, Issue 2, 2008, Pages

  Baltgalvis, Kristen A ^a   Berger, Franklin G ^a   Pena, Maria Marjorette O ^a   Davis, J Mark ^a   Muga, Stephanie J ^b   Carson, James A ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cachexia; Colorectal cancer; Inflammation; Polyps; STAT 3

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CACHEXIA; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE;

ADENOMATOUS POLYPOSIS COLI; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CACHEXIA; ELECTROPORATION; GENE EXPRESSION; GENES, APC; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOTOR ACTIVITY; MUSCLE, SKELETAL; PLASMIDS; SEVERITY OF ILLNESS INDEX; STAT3 TRANSCRIPTION FACTOR;

EID: 38949137388     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00716.2007     Document Type: Article

References (45)

1. Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20: 3364-3375, 2006.
2. al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs 2: 186-197, 2001.
3. Ardies CM. Exercise, cachexia, and cancer therapy: a molecular rationale. Nutr Cancer 42: 143-157, 2002.
4. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6: 401-406, 2003.
5. Barton BE, Murphy TF. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine 16: 251-257, 2001.
6. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2: 381-392, 2002.
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
8. Brozek W, Bises G, Girsch T, Cross HS, Kaiser HE, Peterlik M. Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancer 41: 2347-2354, 2005.
9. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545, 2003.
10. Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 308: 929-934, 2004.
11. Duval D, Reinhardt B, Kedinger C, Boeuf H. Role of suppressors of cytokine signaling (Socs) in leukemia inhibitory factor (LIF)-dependent embryonic stem cell survival. FASEB J 14: 1577-1584, 2000.
12. Espat NJ, Auffenberg T, Rosenberg JJ, Rogy M, Martin D, Fang CH, Hasselgren PO, Copeland EM, Moldawer LL. Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am J Physiol Regul Integr Comp Physiol 271: R185-R190, 1996.
13. Fenton JI, Hursting SD, Perkins SN, Hord NG. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line. Carcinogenesis 27: 1507-1515, 2006.
14. Fujita J, Tsujinaka T, Yano M, Ebisui C, Saito H, Katsume A, Akamatsu K, Ohsugi Y, Shiozaki H, Monden M. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 68: 637-643, 1996.
15. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Interleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Lett 76: 1-4, 1994.
16. Giordano A, Calvani M, Petillo O, Carteni M, Melone MR, Peluso G. Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem 90: 170-186, 2003.
17. Glund S, Deshmukh A, Long YC, Moller T, Koistinen HA, Caidahl K, Zierath JR, Krook A. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56: 1630-1637, 2007.
18. Haddad F, Adams GR. Aging sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J Appl Physiol 100: 1188-1203, 2006.
19. Haddad F, Zaldivar FP, Cooper DM, Adams GR. IL-6 induced skeletal muscle atrophy. J Appl Physiol 98: 911-917, 2005.
20. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003.
21. Iwase S, Murakami T, Saito Y, Nakagawa K. Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 15: 312-316, 2004.
22. Kami K, Senba E. In vivo activation of STAT3 signaling in satellite cells and myofibers in regenerating rat skeletal muscles. J Histochem Cytochem 50: 1579-1589, 2002.
23. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149: 1-38, 2003.
24. Khalfoun B, Thibault F, Watier H, Bardos P, Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol 400B: 589-597, 1997.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25: 402-408, 2001.
26. McCarthy DO. Rethinking nutritional support for persons with cancer cachexia. Biol Res Nurs 5: 3-17, 2003.
27. McClung JM, Mehl KA, Thompson RW, Lowe LL, Carson JA. Nandrolone decanoate modulates cell cycle regulation in functionally overloaded rat soleus muscle. Am J Physiol Regul Integr Comp Physiol 288: R1543-R1552, 2005.
28. Min/+ mouse. J Appl Physiol 99: 2379-2387, 2005.
29. Min/+ mice. J Appl Physiol 98: 2219-2225, 2005.
30. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324, 1990.
31. Price SA, Tisdale MJ. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Res 58: 4827-4831, 1998.
32. Rotter Sopasakis V, Larsson BM, Johansson A, Holmang A, Smith U. Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 47: 1879-1887, 2004.
33. Soda K, Kawakami M, Kashii A, Miyata M. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 62: 332-336, 1995.
34. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162: 655-663, 2003.
35. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684, 1992.
36. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2: 862-871, 2002.
37. Tisdale MJ. The "cancer cachectic factor." Support Care Cancer 11: 73-78, 2003.
38. Tsujinaka T, Ebisui C, Fujita J, Kishibuchi M, Morimoto T, Ogawa A, Katsume A, Ohsugi Y, Kominami E, Monden M. Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem Biophys Res Commun 207: 168-174, 1995.
39. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H, Monden M. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 97: 244-249, 1996.
40. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79, 2002.
41. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab 289: E251-E257, 2005.
42. Williams A, Wang JJ, Wang L, Sun X, Fischer JE, Hasselgren PO. Sepsis in mice stimulates muscle proteolysis in the absence of IL-6. Am J Physiol Regul Integr Comp Physiol 275: R1983-R1991, 1998.
43. Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E, Fujioka N, Mai M, Kasahara T, Fujimoto-Ouchi K, Mori K, Tanaka Y, Matsushima K. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 55: 921-927, 1995.
44. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111: 592-595, 2004.
45. Zhou W, Jiang ZW, Tian J, Jiang J, Li N, Li JS. Role of NF-kappaB and cytokine in experimental cancer cachexia. World J Gastroenterol 9: 1567-1570, 2003.